|
BE787901A
(fr)
|
1971-09-11 |
1972-12-18 |
Freistaat Bayern Represente Pa |
Vaccin antivariolique
|
|
US4769330A
(en)
|
1981-12-24 |
1988-09-06 |
Health Research, Incorporated |
Modified vaccinia virus and methods for making and using the same
|
|
US4603112A
(en)
|
1981-12-24 |
1986-07-29 |
Health Research, Incorporated |
Modified vaccinia virus
|
|
US4722848A
(en)
|
1982-12-08 |
1988-02-02 |
Health Research, Incorporated |
Method for immunizing animals with synthetically modified vaccinia virus
|
|
AU570940B2
(en)
|
1982-11-30 |
1988-03-31 |
United States of America, as represented by the Secretary, U.S. Department of Commerce, The |
Process for producing poxvirus recombinants for expression offoreign genes
|
|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
GB8508845D0
(en)
|
1985-04-04 |
1985-05-09 |
Hoffmann La Roche |
Vaccinia dna
|
|
US5445953A
(en)
|
1991-08-26 |
1995-08-29 |
Immuno Aktiengesellschaft |
Direct molecular cloning of a modified poxvirus genome
|
|
ATE181108T1
(de)
|
1991-08-26 |
1999-06-15 |
Immuno Ag |
Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus
|
|
EP1380651A2
(en)
|
1991-08-26 |
2004-01-14 |
Baxter Healthcare S.A. |
Recombinant fowlpox virus with intact FPV-tk-gene
|
|
WO1994012617A1
(en)
|
1992-11-25 |
1994-06-09 |
International Biotechnology Laboratories, Inc. |
Hepatitis b virus vaccines
|
|
UA68327C2
(en)
|
1995-07-04 |
2004-08-16 |
Gsf Forschungszentrum Fur Unwe |
A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
|
|
WO1998008539A1
(en)
|
1996-08-26 |
1998-03-05 |
Chiron Corporation |
Postinfection human immunodeficiency virus (hiv) vaccination therapy
|
|
US6962708B1
(en)
|
1997-02-28 |
2005-11-08 |
Acambis, Inc. |
Chimeric flavivirus vaccines
|
|
AUPP380598A0
(en)
|
1998-05-29 |
1998-06-25 |
Commonwealth Scientific And Industrial Research Organisation |
Genetically manipulated entomopoxvirus
|
|
US6294176B1
(en)
|
1998-07-10 |
2001-09-25 |
Schering-Plough Veterinary Corp. |
Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
|
|
US8623379B2
(en)
|
2000-03-02 |
2014-01-07 |
Emory University |
Compositions and methods for generating an immune response
|
|
AU2002211948B2
(en)
|
2000-03-02 |
2007-09-13 |
Emory University |
DNA expression vectors and methods of use
|
|
WO2002072754A2
(en)
|
2001-03-08 |
2002-09-19 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mva expressing modified hiv envelope, gag, and pol genes
|
|
EP1279404A1
(en)
|
2001-07-26 |
2003-01-29 |
Istituto Superiore di Sanità |
Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
|
|
US20030170614A1
(en)
|
2001-08-31 |
2003-09-11 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
|
|
US7211378B2
(en)
*
|
2002-01-31 |
2007-05-01 |
Wisconsin Alumni Research Foundation |
Filovirus vectors and noninfectious filovirus-based particles
|
|
WO2003078640A2
(en)
|
2002-03-15 |
2003-09-25 |
Baxter International Inc. |
Recombinant drug-sensitive vaccinia virus as smallpox vaccine
|
|
KR101138067B1
(ko)
|
2002-05-16 |
2012-04-24 |
버베리안 노딕 에이/에스 |
수두 바이러스 게놈내로 삽입된 상동 유전자를 발현하는 재조합 수두 바이러스
|
|
US20060088909A1
(en)
|
2002-05-17 |
2006-04-27 |
Compans Richard W |
Virus-like particles, methods of preparation, and immunogenic compositions
|
|
US9045727B2
(en)
|
2002-05-17 |
2015-06-02 |
Emory University |
Virus-like particles, methods of preparation, and immunogenic compositions
|
|
WO2003106648A2
(en)
|
2002-06-14 |
2003-12-24 |
Diadexus, Inc. |
Compositions and methods relating to breast specific genes and proteins
|
|
DE10249390A1
(de)
|
2002-10-23 |
2004-05-13 |
Ruprecht-Karls-Universität Heidelberg |
Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
|
|
KR20050083839A
(ko)
|
2002-11-25 |
2005-08-26 |
버베리안 노딕 에이/에스 |
두개 이상의 우두 ａｔｉ 프로모터를 포함하는 재조합폭스바이러스
|
|
US20040109876A1
(en)
|
2002-11-25 |
2004-06-10 |
Kureha Chemical Industry Co., Ltd. |
Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV
|
|
JP5052893B2
(ja)
|
2003-02-20 |
2012-10-17 |
アメリカ合衆国 |
ポックスベクターにおける新規の挿入部位
|
|
EP1518932A1
(en)
*
|
2003-09-29 |
2005-03-30 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Modified vaccinia virus Ankara (MVA) mutant and use thereof
|
|
US20060099225A1
(en)
|
2004-04-13 |
2006-05-11 |
Sina Bavari |
Generation of virus-like particles and use as panfilovirus vaccine
|
|
CA2837748C
(en)
|
2004-05-25 |
2016-03-08 |
Oregon Health And Science University |
Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
|
|
EP2319860A3
(en)
|
2004-08-27 |
2011-06-15 |
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services |
Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes
|
|
EP1683870A1
(en)
|
2005-01-24 |
2006-07-26 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vaccines based on the use of MVA
|
|
CA2610292C
(en)
*
|
2005-03-30 |
2015-06-02 |
Minerva Biotechnologies Corporation |
Proliferation of muc1 expressing cells
|
|
US20060286074A1
(en)
|
2005-05-31 |
2006-12-21 |
Yucheng Tang |
Methods for immunotherapy of cancer
|
|
ES2281252B1
(es)
|
2005-07-27 |
2009-02-16 |
Consejo Superior De Investigaciones Cientificas |
Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
|
|
ES2611975T3
(es)
|
2006-06-20 |
2017-05-11 |
Transgene S.A. |
Procedimiento para producir poxvirus y composiciones de poxvirus
|
|
EP2041323A4
(en)
|
2006-07-13 |
2009-10-28 |
Univ Emory |
VIROSOMES, METHODS OF PREPARATION AND IMMUNOGENIC COMPOSITIONS
|
|
EP2062023B2
(en)
|
2006-08-25 |
2016-11-09 |
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services |
Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus
|
|
US20090092628A1
(en)
|
2007-03-02 |
2009-04-09 |
James Mullins |
Conserved-element vaccines and methods for designing conserved-element vaccines
|
|
EP2152730A4
(en)
|
2007-05-02 |
2011-08-03 |
Univ Emory |
ENLARGEMENT OF GLYCOPROTEININCORPORATION IN VIRUSUAL PARTICLES
|
|
EP2468763B1
(en)
|
2007-05-31 |
2014-06-18 |
Academisch Ziekenhuis Leiden h.o.d.n. LUMC |
HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
|
|
US11202775B2
(en)
*
|
2007-09-25 |
2021-12-21 |
Minerva Biotechnologies Corporation |
Methods for treatment of cancer
|
|
WO2009079564A2
(en)
|
2007-12-17 |
2009-06-25 |
Emory University |
Immunogenic compositions and methods of use thereof
|
|
US20110262483A1
(en)
|
2008-11-03 |
2011-10-27 |
Ligocyte Pharmaceuticals, Inc. |
Methods for isolating enveloped virus-based vlps free of infectious agents
|
|
EP2478103A4
(en)
|
2009-09-16 |
2014-02-19 |
Univ Tulane |
LASSAVIRUS-like PARTICLES AND METHOD FOR THE PRODUCTION THEREOF
|
|
AP2012006258A0
(en)
|
2009-10-13 |
2012-06-30 |
Geovax Inc |
Eliciting immune responses using recombinant MVA viruses expressing HIV ENV, GAG and POL antigens.
|
|
DK2488649T3
(da)
|
2009-10-16 |
2019-06-17 |
Us Health |
Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder
|
|
EP2529227B1
(en)
|
2010-01-27 |
2015-10-07 |
Oregon Health & Science University |
Cytomegalovirus-based immunogenic preparations
|
|
CA2790426A1
(en)
|
2010-02-18 |
2011-08-25 |
Emory University |
Vectors expressing hiv antigens and gm-csf and related methods for generating an immune response
|
|
US20120052082A1
(en)
|
2010-04-09 |
2012-03-01 |
Zetra Biologicals, LLC |
Cross-protective influenza vaccine
|
|
TR201902214T4
(tr)
|
2010-04-16 |
2019-03-21 |
Glaxosmithkline Biologicals Sa |
Şempanze adenoviral vektörü-bazlı filovirüs aşıları.
|
|
CN103209701B
(zh)
|
2010-06-11 |
2016-08-03 |
乔治亚大学研究基金公司 |
免疫原性疫苗
|
|
AU2012212463B2
(en)
*
|
2011-01-31 |
2016-07-07 |
Nanotherapeutics, Inc. |
Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses
|
|
CN103945863A
(zh)
|
2011-08-01 |
2014-07-23 |
爱默蕾大学 |
包含配体的vlp及其相关方法
|
|
WO2013059498A1
(en)
|
2011-10-18 |
2013-04-25 |
Geovax, Inc. |
Mva vectors expressing polypeptides and having high level production in certain cell lines
|
|
US9463238B2
(en)
|
2011-12-09 |
2016-10-11 |
Bavarian Nordic A/S |
Recombinant poxvirus vector comprising tetanus toxin fragment C
|
|
CN104853770A
(zh)
|
2012-07-06 |
2015-08-19 |
诺华股份有限公司 |
免疫原性组合物及其应用
|
|
WO2014111733A1
(en)
|
2013-01-21 |
2014-07-24 |
Isis Innovation Limited |
Composition and uses thereof
|
|
WO2015009946A1
(en)
|
2013-07-17 |
2015-01-22 |
Emory University |
Method of increasing immune response to hiv antigens
|
|
AU2014340201B2
(en)
|
2013-10-23 |
2019-02-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
|
|
WO2015066715A1
(en)
*
|
2013-11-04 |
2015-05-07 |
Viracell Advanced Products, Llc |
Virus-like particles and methods related thereto
|
|
JP2017515841A
(ja)
|
2014-05-13 |
2017-06-15 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
腫瘍抗原を発現するポックスウイルス及びｔｉｍ−３に対するモノクローナル抗体を用いた癌治療のための併用療法
|
|
KR102812180B1
(ko)
*
|
2014-09-03 |
2025-05-23 |
버베리안 노딕 에이/에스 |
재조합 변형된 백시니아 바이러스 앙카라 (mva) 필로바이러스 백신
|
|
WO2016068919A1
(en)
|
2014-10-29 |
2016-05-06 |
Geovax, Inc. |
Combination therapy for treating viral reservoirs
|
|
WO2016115116A1
(en)
|
2015-01-12 |
2016-07-21 |
Geovax, Inc. |
Compositions and methods for generating an immune response to a hemorrhagic fever virus
|
|
US10072058B2
(en)
|
2015-04-29 |
2018-09-11 |
Emory University |
Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates
|
|
ES2944314T3
(es)
*
|
2016-01-08 |
2023-06-20 |
Geovax Inc |
Composiciones y procedimientos para generar una respuesta inmunitaria frente a un antígeno asociado a un tumor
|
|
US20190030157A1
(en)
|
2016-02-03 |
2019-01-31 |
Geovax Inc. |
Compositions and Methods for Generating an Immune Response to a Flavivirus
|
|
EP3416978A4
(en)
|
2016-02-16 |
2019-11-06 |
Geovax, Inc. |
MULTIVALENT HIV VACCINE BOOST COMPOSITION AND METHOD OF USE
|
|
CA3026054A1
(en)
|
2016-05-30 |
2017-12-07 |
Geovax Inc. |
Compositions and methods for generating an immune response to hepatitis b virus
|
|
WO2018195447A1
(en)
|
2017-04-20 |
2018-10-25 |
Geovax Labs, Inc. |
Recombinant mva-based hiv immunogens and uses thereof
|
|
US20200171141A1
(en)
|
2017-07-18 |
2020-06-04 |
Geovax, Inc. |
Compositions and Methods for Generating an Immune Response to LASV
|
|
US20210220469A1
(en)
|
2017-08-25 |
2021-07-22 |
Geovax, Inc. |
Immuno-Oncology Compositions and Methods for Use Thereof
|
|
US11311612B2
(en)
|
2017-09-19 |
2022-04-26 |
Geovax, Inc. |
Compositions and methods for generating an immune response to treat or prevent malaria
|
|
WO2020247547A1
(en)
|
2019-06-03 |
2020-12-10 |
Geovax, Inc. |
Cancer vaccine compositions and methods for use thereof
|